Cellular therapies in acute lymphoblastic leukemia.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute lymphoblastic leukemia (ALL) has a high mortality rate in adults, with poor prognoses for relapsed or refractory disease.
• While allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefits pediatric ALL patients, its efficacy in adults is less clear.
• Limited availability of related donors necessitates exploring alternative allo-HSCT sources like cord blood, unrelated donors, and haploidentical donors.

Purpose of the Study:

• To review the current landscape and future directions of adoptive cell therapies for acute lymphoblastic leukemia (ALL).
• To highlight the challenges and advancements in treating adult ALL, particularly relapsed or refractory cases.
• To discuss the potential of novel T-cell and NK-cell-based immunotherapies.

Main Methods:

• Review of clinical investigations and ongoing trials for adoptive cell therapies in ALL.
• Analysis of alternative donor sources for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Exploration of modified T-cell regimens and genetically modified NK cells targeting ALL antigens.

Main Results:

• Donor lymphocyte infusions have shown limited success in relapsed ALL post-HSCT.
• Modified adoptive T-cell therapies, including tumor-targeted and genetically engineered T-cells, are in clinical trials.
• Genetic modification of NK cells to target ALL is a promising strategy for an upcoming clinical trial.

Conclusions:

• Novel adoptive cell therapies, including modified T-cell and NK-cell strategies, hold promise for improving outcomes in adult ALL.
• Further clinical evaluation is required to determine the ultimate efficacy of these innovative immunotherapies.
• Addressing the limitations of current treatments necessitates continued research into advanced cell-based interventions for ALL.